Live feed08:05:00·5dPRReleasevia QuantisnowAbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's DiseaseByQuantisnow·Wall Street's wire, on your screen.ABBV· AbbVie Inc.Health Care
